Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker study
- 21 April 2017
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 141 (1) , 94-101
Abstract
Asymptomatic high‐risk subjects, randomized in the intervention arm of the ITALUNG trial (1,406 screened for lung cancer), were enrolled for the ITALUNG biomarker study (n = 1,356), in which samples of blood and sputum were analyzed for plasma DNA quantification (cut off 5 ng/ml), loss of heterozygosity and microsatellite instability. The ITALUNG biomarker panel (IBP) was considered positive if at least one of the two biomarkers included in the panel was positive. Subjects with and without lung cancer diagnosis at the end of the screening cycle with LDCT (n = 517) were evaluated. Out of 18 baseline screen detected lung cancer cases, 17 were IBP positive (94%). Repeat screen‐detected lung cancer cases were 18 and 12 of them positive at baseline IBP test (66%). Interval cancer cases (2‐years) and biomarker tests after a suspect Non Calcific Nodule follow‐up were investigated. The single test versus multimodal screening measures of accuracy were compared in a simulation within the screened ITALUNG intervention arm, considering screen‐detected and interval cancer cases. Sensitivity was 90% at baseline screening. Specificity was 71 and 61% for LDCT and IBP as baseline single test, and improved at 89% with multimodal, combined screening. The positive predictive value was 4.3% for LDCT at baseline and 10.6% for multimodal screening. Multimodal screening could improve the screening efficiency at baseline and strategies for future implementation are discussed. If IBP was used as primary screening test, the LDCT burden might decrease of about 60%.Keywords
This publication has 26 references indexed in Scilit:
- Allelic imbalance in 1p, 7q, 9p, 11p, 12q and 16q regions in non-small cell lung carcinoma and its clinical association: a pilot studyMolecular Biology Reports, 2013
- Results of the Two Incidence Screenings in the National Lung Screening TrialNew England Journal of Medicine, 2013
- European randomized lung cancer screening trials: Post NLSTJournal of Surgical Oncology, 2013
- Targeting of Low-Dose CT Screening According to the Risk of Lung-Cancer DeathNew England Journal of Medicine, 2013
- Four-Year Results of Low-Dose CT Screening and Nodule Management in the ITALUNG TrialJournal of Thoracic Oncology, 2013
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- A serum circulating miRNA diagnostic test to identify asymptomatic high‐risk individuals with early stage lung cancerEMBO Molecular Medicine, 2011
- Molecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosisLung Cancer, 2010
- Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CTLung Cancer, 2009
- Methods for Assessing Improvement in Specificity When a Biomarker is Combined With a Standard Screening TestStatistics in Biopharmaceutical Research, 2009